Drug Profile
Research programme: herpes virus-like particle vaccines - Eurocine Vaccines
Alternative Names: Herpes simplex virus-like particle vaccines - Eurocine Vaccines; HSV-2 - Eurocine Vaccines; HSV2 therapeutic vaccine program; RED-05Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Redbiotec
- Developer Eurocine Vaccines; Redbiotec; TeselaGen Biotechnology
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus type 2 infections
Most Recent Events
- 21 Nov 2023 Eurocine Vaccines files for patent protection for HSV-2 vaccine programme in USA
- 22 Dec 2022 Pharmacodynamics data from a preclinical studies inHerpes simplex virus type 2 infectionsreleased by Eurocine Vaccines
- 20 Dec 2022 Preclinical trials in Herpes simplex virus type 2 infections in Sweden (Parenteral) prior to December 2022